Kezar Life Sciences, Inc. — Form D
Kezar Life Sciences, Inc. of SOUTH SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2017-08-03. The offering totals $50.0M, of which $50.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-08-03
- Form: D
- Accession: 0001645666-17-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.0M
- Amount sold: $50.0M
- Investors: 24
- Date of first sale: 2017-06-26
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-292025
Issuer
- Name: Kezar Life Sciences, Inc.
- CIK: 0001645666
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 300 UTAH AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Phone: 650-822-5600
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Franklin J Berger | Director | South San Francisco, CA |
| Gerald J Chan | Director | South San Francisco, CA |
| Bihua J Chen | Director | San San Francisco, CA |
| John F Fowler | Director | South San Francisco, CA |
| Michael J Kauffman | Director | South San Francisco, CA |
| Christopher J Kirk | Director | South San Francisco, CA |
| Jean-Pierre J Sommadossi | Director | South San Francisco, CA |
| John F Fowler | Executive Officer | South San Francisco, CA |
| Christopher J Kirk | Executive Officer | South San Francisco, CA |
| Dr. Gerald J Chan | Director | South San Francisco, CA |
| Dr. Jean-Pierre J Sommadossi | Director | South San Francisco, CA |
Other filings by this issuer (1)
More